Application No.: 10/717,290

Amendments to the Claims:
Please amend claims 24 and 41.
The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing:
1-23. (Cancelled)

24. (Currently Amended) A compound represented by formula:



~~and~~ or a pharmaceutically acceptable ~~salts~~ salt, ~~esters~~ ester, ~~prodrugs~~ prodrug, racemic ~~mixtures~~ mixture ~~and~~ or ~~stereoisomers~~ stereoisomer thereof.

25. (Previously Presented) A compound according to claim 24 wherein the compound is a pharmaceutically acceptable salt.

26. (Previously Presented) A compound according to claim 24 wherein the compound is a free base.

27. (Previously Presented) A compound according to claim 24 wherein the compound is an ester or prodrug.

28. (Previously Presented) A compound according to claim 24 wherein the compound is an E oxime isomer.

Application No.: 10/717,290

29. (Previously Presented) A compound according to claim 24 wherein the compound is a Z oxime isomer.

30. (Previously Presented) A method for treating an infection or a disorder related to an infection in a subject in need of such treatment, comprising administering to said subject a therapeutically effective amount of a compound according to the formula:



and pharmaceutically acceptable salts, esters, prodrugs, racemic mixtures and stereoisomers thereof.

31. (Previously Presented) A method according to claim 30 wherein the compound is pharmaceutically acceptable salt.

32. (Previously Presented) A method according to claim 30 wherein the compound is a free base.

33. (Previously Presented) A method according to claim 30 wherein the compound is an ester or prodrug.

34. (Previously Presented) A method according to claim 30 wherein the compound is an E oxime isomer.

35. (Previously Presented) A method according to claim 30 wherein the compound is a Z oxime isomer.

36. (Previously Presented) The method according to claim 30 wherein the compound is administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.

37. (Previously Presented) The method according to claim 30 wherein the compound is administered orally or by injection.

38. (Previously Presented) The method according to claim 30 wherein the subject is a human.

39. (Previously Presented) The method according to claim 30 wherein the compound is administered in combination with one or more antibiotics.

40. (Previously Presented) The method according to claim 39 wherein the antibiotic is selected from the group consisting of penicillin, amoxicillin, azithromycin, erythromycin, ciproflaxin, telithromycin, and cethromycin or a pharmaceutically acceptable salt, ester, or prodrug thereof.

41. (Currently Amended) The method according to Claim 30 wherein the infection is a protozoa infection or bacterial infection ~~and~~ or disorders related to such infections.

42. (Previously Presented) The method according to Claim 41 wherein the infection or disorder is selected from the group consisting of pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis related to infection by

Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, or Peptostreptococcus spp. Pseudomonas spp.; pharynigitis, rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Clostridium diptheriae, or Actinobacillus haemolyticum; respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae, or Chlamydia pneumoniae; uncomplicated skin and soft tissue infections, abscesses and osteomyelitis, and puerperal fever related to infection by Staphylococcus aureus, coagulase-positive staphylococci, S. pyogenes, S. agalactiae, Streptococcal groups C-F, viridans streptococci, Corynebacterium spp., Clostridium spp., or Bartonella henselae; uncomplicated acute urinary tract infections related to infection by S. saprophyticus or Enterococcus spp.; urethritis and cervicitis; and sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus ducreyi, Treponema pallidum, Ureaplasma urealyticum, or Nesseria gonorrheae; toxin diseases related to infection by S. aureus, or Groups A, S. and C streptococci; ulcers related to infection by Helicobacter pylori; systemic febrile syndromes related to infection by Borrelia recurrentis; Lyme disease related to infection by Borrelia burgdorferi; conjunctivitis, keratitis, and dacrocystitis related to infection by C. trachomatis, N. gonorrhoeae, S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, or Listeria spp.; disseminated Mycobacterium avium complex (MAC) disease related to infection by Mycobacterium avium, or Mycobacterium intracellulare; gastroenteritis related to infection by Campylobacter jejuni; intestinal protozoa related to infection by Cryptosporidium spp. odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by Bordetella pertussis; gas gangrene related to infection by Clostridium perfringens or Bacteroides spp.; Skin infection by S. aureus, Propionibacterium acne; atherosclerosis related to infection by Helicobacter pylori and Chlamydia pneumoniae.

Application No.: 10/717,290

43. (Previously Presented) The method according to Claim 42 wherein the infection is selected from the group consisting of pneumonia, otitis-media, sinusitus, bronchitis, tonsillitis, Propionibacterium acne and skin and soft tissue infection.

44. (Previously Presented) The method according to Claim 41 wherein the infection or disorder is selected from the group consisting of bovine respiratory disease related to infection by P. haemolytica., P. multocida, Mycoplasma bovis, or Bordetella spp.; cow enteric disease related to infection by E. coli or protozoa, dairy cow mastitis related to infection by S. aureus, S. uberis, S. agalactiae, S. dysgalactiae, Klebsiella spp., Corynebacterium, or Enterococcus spp.; swine respiratory disease related to infection by A. pleuropneumoniae., P. multocida, or Mycoplasma spp.; swine enteric disease related to infection by E. coli, Lawsonia intracellularis, Salmonella spp., or Serpulina hyodyisinteriae; cow footrot related to infection by Fusobacterium spp.; cow metritis related to infection by E. coli; cow hairy warts related to Infection by Fusobacterium necrophorum or Bacteroides nodosus; cow pink-eye related to infection by Moraxella bovis, cow premature abortion related to infection by protozoa; urinary tract infection in dogs and cats related to infection by E. coli; skin and soft tissue infections in dogs and cats related to infection by S. epidermidis, S. intermedius, coagulase neg. Staphylococcus or P. multocida; and dental or mouth infections in dogs and cats related to infection by Alcaligenes spp., Bacteroides spp., Clostridium spp., Enterobacter spp., Eubacterium spp., Peptostreptococcus spp., Porphfyromonas spp., Campylobacter spp., Actinomyces spp., Erysipelothrix spp., Rhodococcus spp., Trypanosoma spp., Plasmodium spp., Babesia spp., Toxoplasma spp., Pneumocystis spp., Leishmania spp., and Trichomonas spp. and Prevotella spp.

45. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:

Application No.: 10/717,290



and pharmaceutically acceptable salts, esters, prodrugs, racemic mixtures and stereoisomers thereof, in combination with a pharmaceutically acceptable carrier.

46. (Previously Presented) A method for controlling a bacterial infection in a subject, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition according to claim 45.